After six months of treatment with low molecular heparin (enoxaparin), the thrombophilia work-up was repeated, confirming the persistence of hypofibrinogenemia, with a normal quantitative protein S value (74%) and a lower level of activity (32%). This evidence concerns the gene PROS1 and Hypofibrinogenemia.